Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Medtronic Announces Launch of FlexCath Advance(TM) Steerable Sheath, Enhancing the Arctic Front Advance(TM) Cryoballoon System


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-01-15 15:34:18 -

Second-Generation Sheath May Facilitate Easier Access to the Inferior Veins When
                    Treating Paroxysmal Atrial Fibrillation

MINNEAPOLIS - Jan. 15, 2013 - Medtronic, Inc. (NYSE: MDT) today announced Food
and Drug Administration (FDA) clearance and U.S. launch of the FlexCath
Advance((TM)) Steerable Sheath, a new enhancement to the Arctic Front
Advance((TM)) Cryoballoon System. This second-generation sheath has an increased
degree of deflection and response, providing greater ease compared to the
previous generation in reaching the inferior veins of the heart when delivering
and positioning the cryoballoon catheter in the left atrium to treat paroxysmal
atrial fibrillation (PAF).

The Arctic Front Advance System is used in minimally invasive procedures to
isolate the pulmonary 
veins using coolant. Delivered via a catheter, the cryoballoon technology is associated with faster procedure times than point-by- point radiofrequency ablation(1, 2), and better treatment outcomes than drug therapies on the market(3). Additionally, the Arctic Front Advance cryoballoon features the new EvenCool((TM)) Cryo Technology, which optimizes the delivery of coolant inside the balloon; the larger, more uniform cold surface reduces the effort needed to isolate the pulmonary veins, and improves physicians' ability to treat patients with complicated anatomies as compared to the original Arctic Front(®) Cryoballoon. "The FlexCath Advance sheath's ability to maneuver the catheter with a greater range of deflection may help reach the inferior veins and facilitate placement of the cryoballoon, which is a critical step to ensuring treatment success," said Suneet Mittal, M.D., director, Electrophysiology Laboratory, Arrhythmia Institute of the Valley Health System, Ridgewood, NJ. The FlexCath Advance Steerable Sheath has a deflection of 135 degrees, compared to the 90 degree deflection rate of its first-generation predecessor. This greater degree of deflection may allow the cryoballoon to be better maneuvered and positioned within the heart to achieve maximum treatment benefit. The sheath includes the following features: * Radiopaque marker band at 5 millimeters to provide enhanced visibility under fluoroscopy; * Deflection mechanism with an ergonomic handle that optimizes the movement of the sheath; and * Hemostasis valve that allows for introduction, withdrawal and exchanging of catheters and guidewires, while preventing air insertion and minimizing blood loss. "Building upon the Arctic Front System's proven platform, the FlexCath Advance Steerable Sheath augments the overall efficiency of the procedure," said Reggie Groves, vice president and general manager of Medtronic's AF Solutions division. "It completes the Arctic Front Advance System and is the fourth new product we have launched in the U.S. market in two years." About the Arctic Front Advance System The Arctic Front Advance Cryoballoon System and its predecessor have been used to treat more than 50,000 patients in approximately 500 centers across 32 countries. The technologies currently offered include: * The Arctic Front Advance Cryoballoon, which inflates and fills with coolant to isolate the pulmonary veins for the treatment of PAF; * The FlexCath Advance((TM)) Steerable Sheath, which helps deliver and position the cryoballoon in the left atrium; * The Achieve(®) Mapping Catheter, an intra-cardiac electrophysiology recording catheter used to assess pulmonary vein isolation when treating paroxysmal atrial fibrillation; * The Freezor(®) MAX Cardiac CryoAblation Catheter, which is a single-point catheter used to provide additional ablations, as needed; and * The CryoConsole, which houses the coolant, electrical and mechanical components that run the catheters during a cryoablation procedure. About Atrial Fibrillation Atrial fibrillation is the most common and one of the most undertreated heart rhythm disorders, affecting more than 7 million people worldwide. It is estimated that half of all diagnosed atrial fibrillation patients fail drug therapy(4), and if left untreated, patients have up to a five times higher risk of stroke(5) and an increased chance of developing heart failure. PAF is a type of disease in which irregular heartbeats in the upper chambers start and stop suddenly on their own, usually for minutes or days at a time. In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. About Medtronic Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. -end- (1 ) Kojodjojo P, O'Neill MD, Lim PB, et al. Pulmonary venous isolation by antral ablation with a large cryoballoon for treatment of paroxysmal and persistent atrial fibrillation: medium-term outcomes and non-randomised comparison with pulmonary venous isolation by radiofrequency ablation. Heart. September 2010;96(17):1379-1384. (2) Sorgente A, Chierchia GB, Capulzini L, et al. Atrial fibrillation ablation: a single center comparison between remote magnetic navigation, cryoballoon and conventional manual pulmonary vein isolation. Indian Pacing Electrophysiol J. December 26, 2010:10(11):486-495. (3 )Medtronic, Inc. Arctic Front Cardiac CryoAblation Catheter clinical reports, in support of FDA premarket approval. (4 )JAMA 2001; 285:2370-5. (5) Fuster et al. Journal of the American College of Cardiology. 2006; 48:854-906. Contacts: Tracy McNulty Public Relations +1-763-526-2492 Jeff Warren Investor Relations +1-763-505-2696 This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Medtronic, Inc. via Thomson Reuters ONE [HUG#1669664]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com